Market Research, Feasibility Studies, and Business Plan Services for Pharmaceutical Company Sector in Italy
October 29, 2025
12 min read
COMMERCIAL EXCELLENCE
Loading...
Strategic guidance and institutional-grade solutions customized for your enterprise objectives.
Talk to a Financial Expert
Schedule a complimentary 30-minute discovery call to discuss your enterprise’s financial trajectory.
By submitting, you agree to our Privacy Policy.
Table of Contents
Italy stands as a cornerstone of the European pharmaceutical landscape—a market characterized by a sophisticated healthcare system, a large and aging population, and a steadfast commitment to medical innovation. For a Pharmaceutical Company, whether an innovative biotech, a generics manufacturer, or an established multinational, the Italian market presents a significant opportunity. However, this opportunity is guarded by one of the most complex and regulated reimbursement and pricing systems in the world.
Navigating the pathway from molecule to market in Italy requires more than clinical efficacy; it demands a strategic, data-driven, and meticulously planned approach. Success hinges on understanding the intricate dance between scientific value, economic assessment, and regional healthcare politics.
This comprehensive guide will dissect the three indispensable pillars for a successful market entry strategy in the Italian pharmaceutical sector: deep Market Research, a rigorous Feasibility Study, and a compelling Business Plan. Mastering this process is critical to secure pricing and reimbursement, forge effective market access, and achieve commercial success.
Part 1: Market Research for the Italian Pharmaceutical Market - Analyzing the Therapeutic Landscape
Market Research in pharma is the equivalent of Phase III clinical trials for your commercial strategy. It transforms a scientific claim ("our new oncology drug improves progression-free survival") into a validated market insight ("our oncology drug addresses an unmet need in second-line NSCLC treatment within the Lombardy and Lazio regions, where patient volume is high and current therapies are burdened by significant side effects and cost").
Key Components of Effective Pharmaceutical Market Research in Italy:
Disease Landscape & Epidemiology:
Burden of Illness: Quantifying the prevalence and incidence of the disease your product treats. An aging population makes chronic diseases like diabetes, cardiovascular disease, and Alzheimer's areas of high focus for the Servizio Sanitario Nazionale (SSN).
Patient Pathways (Percorso Diagnostico Terapeutico Assistenziale - PDTA): Mapping the patient journey from diagnosis to treatment within the Italian system. Understanding who the prescribing physicians are (hospital specialists, GPs) and where treatment is administered (hospital, territory) is crucial.
Unmet Medical Need: Analyzing the limitations of current Standard of Care (SoC)—whether in efficacy, safety, tolerability, or administration route—to define your product's value proposition.
Competitive Intelligence & Benchmarking:
Competitor Product Analysis: Profiling existing and pipeline competitors. This includes their mechanism of action, clinical data, pricing, market share, and key messaging.
SWOT Analysis: A structured analysis of competitors and your own product to identify strategic advantages, weaknesses in their profiles, and potential threats from new market entrants.
Key Opinion Leader (KOL) Mapping: Identifying the leading clinicians, researchers, and hospital department heads in your therapeutic area in Italy. Their influence on treatment guidelines and regional formularies is profound.
Market Sizing & Financial Flows:
Patient Pool Sizing: Estimating the number of treatable patients in Italy, often broken down by region. This involves analyzing hospital discharge records, prescription data, and epidemiological databases.
Market Value & Growth: Assessing the current size and growth trajectory of the therapeutic class in Italy. Is the market expanding due to new innovations or contracting due to generics erosion?
Understanding the "Payer": In Italy, the payer is multifaceted. It includes the national government (AIFA), regional health authorities (ASL), and hospital pharmacy budgets. Research must understand the pressures and incentives for each.
Regulatory & HTA Landscape:
AIFA (Agenzia Italiana del Farmaco): The national regulatory agency for drugs. Understanding the AIFA registration process is the first step.
Pricing & Reimbursement (P&R) Pathways: This is the core challenge. Research must focus on the pathways for:
Class C (Categoria C): Drugs not reimbursed by the SSN.
Class H (Categoria H): Hospital-only drugs.
Transparency List (Prontuario Farmaceutico Nazionale): For reimbursable drugs administered in the community.
Health Technology Assessment (HTA): AIFA's Commissione Tecnico-Scientifica (CTS) and Comitato Prezzi e Rimborso (CPR) evaluate the clinical, economic, and ethical impact of a new drug. Early understanding of their evidentiary requirements is vital.
Part 2: The Feasibility Study - Assessing Commercial Viability and Market Access
Market research confirms the opportunity; the Feasibility Study determines whether your specific product can successfully navigate the Italian system to achieve market access and financial sustainability. It answers the critical question: "Given the clinical profile and the market dynamics, can we secure a favorable price and reimbursement status and build a viable business case?"
Core Elements of a Pharmaceutical Feasibility Study in Italy:
Regulatory & Market Access Feasibility:
P&R Strategy Development: Defining the target product profile for HTA submission. This involves determining the optimal positioning (first-line, second-line), identifying the relevant comparator, and building the core value dossier.
Pricing Scenario Modeling: Developing a target price range based on external reference pricing (ERP) from other EU countries, the price of the current SoC, and the product's incremental clinical benefit. This includes modeling for potential Managed Entry Agreements (MEAs), such as payment-by-result or cost-sharing schemes.
Brand vs. Generics/Biosimilars Strategy: Assessing the threat and timing of market erosion from generics and defining a lifecycle management plan.
Clinical & Medical Feasibility:
Real-World Evidence (RWE) Planning: Assessing the need for and planning Italian observational studies or registries to generate local data that supports value claims and satisfies MEA requirements.
Clinical Guideline Adoption: Developing a strategy to get your product included in national and regional clinical guidelines (PDTAs).
Commercial & Operational Feasibility:
Go-to-Market Model: Deciding on the commercial footprint. Will you use a direct sales force, a distributor model, or a hybrid? For hospital drugs, a key account management model targeting hospital pharmacists and clinicians is often essential.
Supply Chain & Logistics: Ensuring compliance with Italian traceability laws (bollino) and planning for distribution through wholesalers or direct-to-hospital channels.
Field Force Sizing & Structure: Determining the optimal size and structure of the medical and sales teams based on the target customer universe (e.g., oncologists, cardiologists, hospital pharmacies).
Economic and Financial Feasibility:
Investment Requirements: Projecting costs for AIFA submission fees, market access consultancy, local safety officer (PV), initial inventory, and commercial team setup.
Revenue Modeling: Building a bottom-up forecast based on patient share, treated patient numbers, and net price (after mandatory discounts and rebates). This model must account for the typical launch curve and the time to achieve market access.
Profitability & ROI Analysis: Calculating the Net Present Value (NPV) and Internal Rate of Return (IRR) of the Italian market entry project, providing a clear financial picture for corporate decision-makers.
Part 3: The Business Plan - The Strategic Roadmap for Investment and Launch
The Business Plan is the master document that synthesizes all analysis into a persuasive narrative and an operational roadmap. It is the essential tool for securing internal board approval, allocating global budget, and attracting potential local partners.
What Corporate Leadership and Investors Look for in a Pharmaceutical Business Plan for Italy:
Executive Summary: A powerful, concise overview that captures the product's clinical differentiation, the compelling market opportunity in Italy, the clear Market Access pathway, and the financial potential.
Product & Value Proposition: A detailed description of the drug, its mechanism of action, and its unique clinical and economic value story tailored for Italian HTA bodies.
Market Analysis Summary: Evidence of a deep understanding of the Italian healthcare system, the competitive landscape, and the specific needs of patients, physicians, and payers.
Market Access & Pricing Strategy: The core of the plan. A transparent, step-by-step roadmap for AIFA negotiation, including the target reimbursement class (H or Prontuario), the desired price, and the strategy for Managed Entry Agreements.
Marketing & Sales Strategy: A tactical plan for post-access commercial execution. This includes:
KOL Engagement & Advocacy Plan.
Medical Education Strategy.
Sales Force Strategy and Target Account Plan.
Management & Operations: An outline of the local organization, including the Country Manager, Regulatory Affairs, Market Access, and Medical Affairs roles.
Financial Projections: The quantitative heart of the plan. It must be robust, transparent, and include:
5-Year Profit & Loss Statement (from launch year).
Cash Flow Forecast.
Key Assumptions (e.g., time to market access, patient share, net price, gross-to-net deductions).
Risk Mitigation & Scenario Analysis: A clear-eyed assessment of risks (e.g., negative AIFA outcome, competitor launch) and contingency plans.
How Aviaan Can Be Your Strategic Partner in the Italian Pharmaceutical Market
The journey to launch in Italy is a high-stakes process where specialized expertise makes the difference between rapid access and costly delays. Aviaan acts as your embedded strategic partner, providing the local market intelligence and strategic acumen needed to optimize your market entry.
Our tailored advisory services for Pharmaceutical Companies targeting Italy include:
Granular Market & HTA Intelligence: We provide deep insights into AIFA's decision-making patterns, regional access variations, and competitor pricing strategies, enabling you to build a data-driven value dossier.
Pricing & Market Access Strategy: We help you develop a winning P&R strategy, including target price positioning, the design of compelling Managed Entry Agreement proposals, and support throughout the AIFA negotiation process.
Commercial Model Optimization: We assist in designing the most efficient and effective commercial organization for Italy, from sizing the field force to selecting and managing distribution partners.
Financial Modeling & Business Case Development: We build robust, defensible financial models that accurately reflect the unique gross-to-net dynamics and phased revenue build-up of the Italian pharmaceutical market.
Investor & Board-Ready Business Plans: We specialize in crafting comprehensive, credible business plans that articulate a compelling investment case, providing the clarity and confidence needed for global leadership to greenlight the Italian investment.
Case Studies: From Market Access Strategy to Commercial Leadership
Case Study 1: Launching a Novel Orphan Drug for a Rare Neurological Disease
The Client: A mid-sized European biotech company with a newly approved orphan drug for a rare, life-limiting neurological condition affecting approximately 1,200 patients in Italy.
The Challenge: The client had EU approval but faced the challenge of securing a premium price in a cost-constrained system. They needed a robust strategy for AIFA approval and a feasible commercial model for a ultra-orphan indication, requiring a €3 million investment for the Italian launch.
How Aviaan Helped:
Market Research: We conducted a deep analysis of the orphan drug landscape in Italy, identifying precedents for high-price therapies and the specific evidentiary requirements of AIFA's CTS. We mapped the entire Italian patient pathway, identifying the 20 key clinical centers managing over 80% of the treatable population.
Feasibility Study: We developed a strategy centered on a payment-by-result Managed Entry Agreement. The feasibility study modeled various outcome-based scenarios, demonstrating how the risk-sharing mechanism could mitigate AIFA's budget impact concerns. We recommended a "virtual" commercial model centered on a small team of Medical Science Liaisons (MSLs) and Key Account Managers.
Business Plan & Outcome: The business plan presented a compelling narrative of addressing a high-unmet need with a innovative financing solution. The financial model was built on a high net price, justified by the MEA, with low commercial overhead. The client secured internal funding. The well-prepared AIFA submission, supported by a proactive MEA proposal, led to a positive reimbursement decision within 10 months. The product achieved >60% patient share within the identified centers in its first 18 months on the market.
Case Study 2: Portfolio Expansion for a Generics Company with a Biosimilar
The Client: An established generics and biosimilars manufacturer aiming to launch a biosimilar of a high-cost monoclonal antibody used in oncology and rheumatology.
The Challenge: The Italian market for the originator product was worth over €250 million, but biosimilar penetration was low due to physician conservatism and complex regional procurement practices. The client needed a business plan to secure a €5 million investment for an aggressive market entry to capture significant share.
How Aviaan Helped:
Market Research: Our research quantified the potential for biosimilar adoption, identifying regional "biosimilar champions" in hospital pharmacy and clinical leadership. We analyzed tender histories and found that regions like Emilia-Romagna and Veneto were more advanced in biosimilar uptake, providing a beachhead strategy.
Feasibility Study: The study concluded that competing on price alone was insufficient. A "value-added" strategy was needed, including contracts with guaranteed supply, support for patient support programs, and robust pharmacovigilance. The financial model focused on volume over margin, requiring a significant initial price discount to gain tender positions.
Business Plan & Outcome: The business plan outlined a "regional rollout" strategy, targeting the most biosimilar-friendly regions first. It included a dedicated hospital tender team and a medical affairs plan to address physician educational needs. The financial projections showed a path to profitability through rapid volume growth and low-cost operations. The business plan justified the €5 million investment. The client successfully won its first regional tender in Emilia-Romagna, achieving a 30% share of the biosimilar market within that region in the first year, establishing a strong foothold for national expansion.
Conclusion: Prescribe a Strategic Foundation for Your Italian Launch
The Italian pharmaceutical market offers substantial rewards for companies that combine scientific innovation with a strategically sound and expertly executed market entry plan. Approaching AIFA, regional payers, and clinicians without the foundation of comprehensive market research, a rigorous feasibility study, and a meticulously crafted business plan is a significant risk that can lead to delayed access, suboptimal pricing, and commercial underperformance.
These documents are the strategic instruments that align your clinical data with market needs, illuminate the path to reimbursement, and build the confidence required to secure investment and achieve launch excellence.
Ready to navigate the complexities of the Italian pharmaceutical market with precision and confidence?
Contact Aviaan today for a confidential consultation. Our team of life sciences and market access strategy experts is ready to provide a preliminary assessment of your product's potential in Italy and develop a tailored strategic roadmap for your success.
Partner with Aviaan Advisory today to unlock your business’s full potential. Our team of experts is here to provide tailored solutions and guide you every step of the way.